Validation of MR-Based Attenuation Correction of a Newly Released Whole-Body Simultaneous PET/MR System

Table 1

Basic information of patients.

Patient	Sex	Age (years)	Height (cm)	Weight (kg)	Diagnosis	Dose (mCi)	Duration of PET/MRI after injection (min)	Clinical indication
1	F	55	162.0	62.0	Lung cancer	7.39	61	Follow-up
2	F	71	152.0	70.0	Cerebral metastasis	8.33	98	Diagnosis
3	M	57	172.0	68.0	Rectal cancer	8.65	114	Restaging
4	M	65	180.0	87.5	Lymphoma	10.49	99	Staging
5	M	64	170.0	64.0	Esophageal cancer, lung cancer	8.22	104	Staging
6	M	66	167.0	76.0	Pancreatic cancer	9.52	146	Staging
7	M	17	174.0	72.0	Thyroid cancer	8.60	94	Diagnosis
8	M	69	162.0	67.0	Enterocoelic sarcoma	8.65	120	Staging
9	F	73	157.0	63.0	Ovarian cancer	7.05	96	Staging
10	F	50	165.0	54.0	Pancreatic cancer	6.99	87	Staging
11	F	65	163.0	58.0	Cholangiocarcinoma	6.87	101	Staging
12	M	66	164.0	51.0	Esophageal cancer	6.13	102	Staging
13	F	51	161.0	67.0	Rectal cancer	8.01	90	TRE
14	F	68	161.0	63.0	Lung cancer	7.33	87	Staging
15	M	46	170.0	105.0	Liver cancer	13.61	162	Diagnosis
16	M	62	175.0	75.0	Lung cancer	9.33	88	Staging
17	M	70	170.0	70.0	Duodenal cancer	8.82	96	Staging
18	M	70	162.0	69.0	Lung cancer	8.20	119	Staging
19	M	64	164.0	61.0	Colon cancer	8.50	117	Staging
20	M	63	168.0	68.0	Gastric cancer	8.57	94	TRE
21	M	65	172.0	71.0	Colon cancer	8.85	107	Staging
22	M	69	170.0	72.0	Pancreatic cancer	9.99	115	Diagnosis
23	M	54	151.0	52.0	Liver cancer	6.40	66	Staging
24	M	46	173.0	84.0	Liposarcoma in teres major	10.71	103	Staging
25	M	60	171.0	73.8	Liver cancer	3.64	94	TRE
26	M	75	173.0	74.0	Liver cancer	9.38	107	Restaging
27	F	60	156.0	56.0	Duodenal cancer	6.69	114	Staging
28	M	51	174.0	85.0	Liver cancer	10.08	93	Diagnosis
29	M	61	172.0	70.5	Lymphoma	8.45	82	Diagnosis
30	F	69	156.0	60.0	Liver cancer	8.63	95	Diagnosis
Mean		60.7	166.2	69.0		8.40	101.7
SD		11.2	7.1	11.1		1.72	19.6

Note: M, male; F, female; SD, standard deviation; TRE, therapy-response evaluation.